Case Report: Rare factor V inhibitor found in a patient with ulcerative colitis during latent tuberculosis infection
-
By
-
Yaodong Wang
-
Na Li
-
Xiaoxin Li
-
Jinchun He
-
June 2, 2026
-
Clinical Scorecard: Uncommon Factor V Inhibitor Detected in a Patient with Ulcerative Colitis and Latent Tuberculosis Infection: A Case Study
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | Presence of internal FV inhibitors leading to reduced FV activity. |
| Target Population | |
| Care Setting | |
Key Highlights
- AFVD is characterized by a relative deficiency of coagulation factor V due to FV inhibitors.
- Infection is a common secondary cause of FV inhibitors.
- Traditional treatments targeting primary disease did not improve patient condition.
- This case is the first report of FV inhibitor in patients with UC during LTBI.
Guideline-Based Recommendations
Diagnosis
- Use APTT/PT mixing studies to preliminarily judge the presence of inhibitors.
Management
- Eliminate inhibitors through immunosuppressive or immunomodulatory strategies.
Monitoring & Follow-up
- Monitor for prolonged APTT and PT in patients with unexplained bleeding.
Risks
- Anti-tuberculosis drugs can cause drug-induced liver injury.
Patient & Prescribing Data
A 48-year-old male with ulcerative colitis and latent tuberculosis.
Immunoglobulin regimen was beneficial in clearing FV inhibitors.
Clinical Best Practices
- Screen for latent tuberculosis before initiating immunosuppressive therapy.
Related Resources & Content
